Get the Stockscreener App
2.38
4.85%
0.11
Kyverna Therapeutics Inc stock is traded at $2.38, with a volume of 463.78K.
It is up +4.85% in the last 24 hours and down -14.39% over the past month.
See More
Previous Close:
$2.27
Open:
$2.24
24h Volume:
463.78K
Relative Volume:
1.33
Market Cap:
$102.75M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-4.80%
1M Performance:
-14.39%
6M Performance:
-62.75%
1Y Performance:
-91.15%
1-Day Range:
$2.20
$2.455
1-Week Range:
$2.20
$2.62
52-Week Range:
$2.20
$27.19
Kyverna Therapeutics Inc Stock (KYTX) Company Profile
Name
Kyverna Therapeutics Inc
Sector
Industry
Phone
(510) 626-8331
Address
5980 HORTON STREET, EMERYVILLE
Compare KYTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KYTX
Kyverna Therapeutics Inc
|
2.38 | 102.75M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
503.20 | 129.22B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
658.48 | 71.99B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
615.02 | 37.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
283.34 | 36.68B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
251.98 | 27.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Kyverna Therapeutics Inc Stock (KYTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-24 | Initiated | UBS | Buy |
| Oct-09-24 | Initiated | Rodman & Renshaw | Buy |
| Jul-03-24 | Initiated | H.C. Wainwright | Neutral |
| Mar-04-24 | Initiated | JP Morgan | Overweight |
| Mar-04-24 | Initiated | Leerink Partners | Outperform |
| Mar-04-24 | Initiated | Morgan Stanley | Overweight |
| Mar-04-24 | Initiated | Wells Fargo | Overweight |
View All
Kyverna Therapeutics Inc Stock (KYTX) Latest News
Investors Who Lost Money on Kyverna Therapeutics, Inc. (KYTX) Should Contact Levi & Korsinsky About Pending Class ActionKYTX - ACCESS Newswire
Kyverna Therapeutics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More Information – KYTX - ACCESS Newswire
Kyverna Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights – KYTX - ACCESS Newswire
Kyverna Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Kyverna Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 7, 2025KYTX - ACCESS Newswire
Kyverna Therapeutics Inc expected to post a loss of 84 cents a shareEarnings Preview - TradingView
Kyverna Therapeutics stock hits 52-week low at $2.24 - Investing.com
Kyverna: 2 Myasthenia Gravis Program Catalysts On Deck In 2025 - Seeking Alpha
Kyverna Therapeutics stock hits 52-week low at $2.24 By Investing.com - Investing.com Australia
Notice to Long-Term Shareholders of Driven Brands Holdings, - GlobeNewswire
Kyverna Therapeutics (KYTX) to Release Quarterly Earnings on Tuesday - MarketBeat
Lupus Nephritis Clinical and Non-Clinical Studies, Key - openPR
GordonMD® Invests in Clinical Stage Cell Therapy Company Kyverna - Business Wire
Notice to Long-Term Shareholders of Archer-Daniels-Midland - GlobeNewswire
Notice to Long-Term Shareholders of Archer-Daniels-Midland Co. (NYSE: ADM); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Kyverna Therapeutics, Inc. (Nasdaq: KYTX); and Mercury Systems, Inc. (Nasdaq: MRCY): Grabar Law Office is Investigating Claims on Your Behalf - GlobeNewswire Inc.
Notice to Long-Term Shareholders of Fluence Energy, Inc. - GlobeNewswire
Long-Term Shareholder Notice: Fluence Energy, Inc. (NASDAQ: - GlobeNewswire
KYTX stock touches 52-week low at $2.49 amid market challenges - Investing.com Australia
Shareholders that lost money on Kyverna Therapeutics, Inc.(KYTX) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Rhumbline Advisers Purchases 6,153 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - Defense World
Kyverna Therapeutics stock hits 52-week low at $2.64 By Investing.com - Investing.com Australia
Kyverna Therapeutics to Present at the Leerink Partners Global B - GuruFocus.com
Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference - PR Newswire
Kyverna Therapeutics stock hits 52-week low at $2.64 - Investing.com
Levi & Korsinsky Notifies Shareholders of Kyverna Therapeutics, Inc. (KYTX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Kyverna Therapeutics To Present At The Leerink Partners Global Biopharma Conference - MENAFN.COM
KYTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Kyverna Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Head-To-Head Survey: Pluri (NASDAQ:PLUR) & Kyverna Therapeutics (NASDAQ:KYTX) - Defense World
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 7, 2025 in Kyverna Therapeutics, Inc. LawsuitKYTX - ACCESS Newswire
3 US Penny Stocks With Market Caps Under $200M - Yahoo Finance
KYTX stock touches 52-week low at $2.78 amid sharp annual decline - MSN
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives $25.71 Consensus Price Target from Analysts - Defense World
KYTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Kyverna Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Leerink Partnrs Issues Optimistic Estimate for KYTX Earnings - MarketBeat
KYTX stock touches 52-week low at $2.78 amid sharp annual decline By Investing.com - Investing.com South Africa
Equities Analysts Set Expectations for KYTX FY2025 Earnings - Defense World
What Makes Kyverna Therapeutics, Inc. (KYTX) a New Buy Stock - MSN
KYTX Deadline: KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit - Morningstar
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics - Kilgore News Herald
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadli - GuruFocus.com
2025-02-07 | FINAL REMINDER KYTX DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Kyverna Therapeutics, Inc. Investors to Participate in the Class Action Lawsuit | NDAQ:KYTX | Press Release - Stockhouse Publishing
Kyverna Therapeutics, Inc. Class Action: The Gross Law Firm Reminds Kyverna Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 7, 2025KYTX - Finansavisen
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics - TradingView
The Gross Law Firm Reminds Kyverna Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 7, 2025KYTX - PR Newswire
Investors in Kyverna Therapeutics, Inc. Should Contact The - GlobeNewswire
Investors in Kyverna Therapeutics, Inc. Should Contact The Gross Law Firm Before February 7, 2025 to Discuss - EIN News
KYTX DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Kyverna Therapeutics, Inc. Investors ... - The Bakersfield Californian
2025-02-06 | FINAL KYTX DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Kyverna Therapeutics, Inc. Investors to Join the Class Action Lawsuit | NDAQ:KYTX | Press Release - Stockhouse Publishing
Kyverna Therapeutics Inc Stock (KYTX) Financials Data
There is no financial data for Kyverna Therapeutics Inc (KYTX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Kyverna Therapeutics Inc Stock (KYTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Jones Ryan Alexander | Chief Financial Officer |
May 28 '24 |
Option Exercise |
0.73 |
18,016 |
13,152 |
43,950 |
0.19%
1.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):